Contribute Try STAT+ Today

For the 1.6 million people in America living with type 1 diabetes, a continuous glucose monitor can be a lifesaver.

Since the first CGM was approved by the Food and Drug Administration in 1999, the diabetes community has advocated for lower prices and better insurance coverage for the quarter-sized devices, which regularly sample a proxy for blood glucose levels and can sound an alarm when they swing too high or too low. The cost-cutting has had an unexpected side effect: Today, glucose monitors are so cheap they’ve spawned a new crop of digital health startups selling the devices to consumers, many of whom don’t have diabetes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.